Introduction
Deep remission is emerging as an important treatment goal for patients with ulcerative colitis [UC] to improve outcomes beyond clinical remission and towards modifying the disease course. 1 The currently accepted definition of clinical remission includes normalization of patient-reported symptoms [rectal bleeding and stool frequency] and endoscopic healing. 2 Regulatory agencies support such a composite of symptomatic and endoscopic improvement as a clinical trial outcome in the evaluation of treatment for UC. 3 The European Medicines Agency [EMA] guidance on the definition of remission in UC also cites the Mayo Clinic Score with a preferred definition of remission as an ES of 0, although a score of 0 or 1 on the ES, RBS or SFS is also an acceptable definition. 4 However, currently there is no standardized definition for assessing deep remission in UC. 5, 6 In principle, deep remission is intended to represent complete disease quiescence with ES, RBS and SFS of 0 [although it is debatable whether increased stool frequency is completely reversible, probably due to structural damage in some patients] and should be the clinical target that physicians strive to achieve for their patients. More analyses are needed to assess the utility of deep remission as a clinical outcome in patients with UC.
Moreover, studies of anti-tumour necrosis factor alpha [TNFα] agents have also suggested a positive correlation between high trough serum drug concentrations and favourable therapeutic outcomes, which include endoscopic healing. 7, 8 A study by Paul et al. showed that mean trough serum concentrations of infliximab were higher in patients with UC in clinical remission [1.9 µg/mL] compared with patients with active disease [0.9 µg/mL; p = 0.01]. 7 The impact of therapeutic drug monitoring on clinical remission was also demonstrated in a distinct cohort of patients who required dose intensification. An increase in infliximab trough levels was strongly associated with clinical remission after infliximab dose optimization [p = 0.0001]. 7 A recent analysis confirmed that infliximab trough concentrations during maintenance therapy were associated with endoscopic and histological healing in patients with UC. 9 The association between drug trough serum concentrations and improved clinical and endoscopic outcomes suggests that incorporation of therapeutic drug monitoring into clinical practice may allow clinicians to optimize treatment by maintaining effective drug concentrations over time. However, the usefulness of proactive drug monitoring has not been established.
Vedolizumab In previous studies, higher rates of endoscopic healing were associated with higher vedolizumab trough serum concentrations in patients with UC. 13, 14 Understanding the relationship between trough serum drug concentrations and deep remission may help to inform clinicians about optimal treatment strategies, thereby increasing the likelihood of achieving this favourable outcome in patients with UC.
Here, we describe a post hoc analysis of the phase 3 GEMINI 1 trial 10 to determine the efficacy of vedolizumab in inducing deep remission at Week 52 in patients with UC. The correlation between vedolizumab trough serum concentrations and rates of deep remission was also explored.
Materials and Methods

GEMINI 1 study design and analysis populations
The GEMINI 1 study [NCT00783718] evaluated the efficacy and safety of vedolizumab 300 mg in the treatment of patients with UC as induction and maintenance therapy for up to 52 weeks. 10 The design and outcomes of this trial have been described previously 10 ; the protocol was approved by an investigational review board at each study centre, and all patients provided their written informed consent. For the current study, all authors had access to the study data and approved the final manuscript.
Briefly, patients with moderately to severely active UC received vedolizumab induction therapy consisting of either double-blind or open-label vedolizumab 300 mg at Weeks 0 and 2. Patients with a clinical response at Week 6 were then re-randomized to placebo or maintenance vedolizumab 300 mg Q8W or Q4W with no dose escalation, and patients who did not achieve a clinical response by Week 6 received open-label vedolizumab 300 mg Q4W. All patients were followed to Week 52. The induction intention-to-treat [ITT] population consisted of all randomized patients who received any amount of blinded study drug during Weeks 0-6. The maintenance ITT population consisted of all randomized patients who received vedolizumab during the induction phase, met the protocol definition of clinical response at Week 6, were randomized and received any amount of double-blind study drug in the maintenance phase.
This analysis included all vedolizumab-treated patients who were responders at Week 6 [induction ITT population; Supplementary Figure S1 
Analysis endpoints
Four definitions of deep remission in the maintenance ITT population were delineated based on the stringency of remission criteria. The four definitions are listed in order from most stringent to least stringent in 
Results
Baseline demographics and patient characteristics
At Week 6, a total of 373 patients responded to vedolizumab induction therapy and were re-randomized to maintenance placebo Table 2 . 
Deep remission rates
Endoscopic score during the maintenance phase
ES during the maintenance phase for the three treatment arms is shown in Figure 2 . Among those who had endoscopy at Week 52, 45.5% and 50.6% of patients had an ES of 0 in the vedolizumab Q8W and Q4W groups, respectively, vs 22.4% in the placebo group. For patients with an ES of 0 or 1, the corresponding figures were 81.9% and 83.5%, respectively, vs 51.0%. The proportion of patients with an ES of 0 who reported an SFS of 0 at Week 52 was 85.0% and 76.0% in the vedolizumab Q8W and Q4W groups, respectively, and 82.0% in the placebo group. A similar proportion of patients with an ES of 0 reported an SFS of 1 [12% in the Q8W group; 22% in the Q4W group; 18% in the placebo group] or 2 [3% in the Q8W group; 3% in the Q4W group; no patients in the placebo group].
Comparison of endoscopic, rectal bleeding and stool frequency subscores
The results of the concordance analysis between patient-reported symptoms [RBS and SFS] and ES are shown in Table 3 for the pooled ITT population. For an ES of 0 or 1, combining the RBS and SFS offered the highest PPV, the RBS offered the highest NPV and sensitivity, while the SFS offered higher specificity. The associations were less clear when an ES of 0 was considered. The combination of RBS and SFS still offered the highest PPV and specificity, while both the combined and the individual symptom scores offered high NPV and sensitivity.
Analysis of deep remission by vedolizumab trough serum concentrations
There was a trend towards an association of higher rates of deep remission at Week 52 with higher vedolizumab trough steadystate serum concentrations, for all definitions of deep remission. 
Discussion
The post hoc analysis presented here has shown that patients treated with vedolizumab as maintenance were statistically significantly more likely to achieve deep remission as measured by improvements in endoscopic healing and symptomatic patient-reported outcomes, than were those who received placebo. More than 40% of vedolizumab-treated patients vs up to 15.9% of placebo-receiving patients achieved deep remission after 46 weeks of follow-up. The differences in deep remission rates compared with placebo were statistically significant for each dose regimen of vedolizumab [Q4W and Q8W] and the two dosing regimens were similarly effective. These benefits of vedolizumab treatment were found with respect to all four definitions of deep remission, including the most stringent [definition 1] that required both endoscopic remission and symptomatic improvement. Higher rates of deep remission compared with placebo were also demonstrated using less stringent criteria. The GEMINI 1 study showed that rates of durable clinical remission and mucosal healing were higher among vedolizumab-treated patients than among placebo-treated patients.
This post hoc analysis of GEMINI 1 data extends these findings by providing an important and clinically relevant perspective on the effectiveness of vedolizumab in achieving deep remission in patients with UC. These data inform a progressive and evolving approach to measuring treatment success that goes beyond the standard phase 3 clinical trial end points. Furthermore, these data support the need for guideline-mediated standardization of criteria for defining deep remission in clinical practice.
Current recommendations for defining clinical remission in patients with UC include both patient-reported measures [rectal bleeding and stool frequency], which reflect the burden of the disease on patients, and endoscopic measures. 3, 4 The use of both patient-reported and endoscopic measures is supported by the observation that normalization of stool frequency does not always correlate with mucosal healing and, in patients with mucosal healing, the highest quality of life is reported by patients who achieve normalization of stool frequency. 17, 18 The findings from the current study also support this, with some degree of abnormal stool frequency in a proportion of patients with mucosal healing [ES of 0; normal or inactive disease] in both the vedolizumab and the placebo groups. Although UC is traditionally regarded as a disease that is limited to the mucosa, accumulating evidence suggests that fibrosis is a common occurrence in UC. 19 Fibrotic changes are likely to have important clinical consequences, even in the absence of strictures, and may account for the discrepancy between mucosal healing and stool frequency. An analysis of the concordance between the individual symptom scores and ES in the pooled ITT population provides further support for the use of both RBS and SFS in the evaluation of clinical remission. While SFS performed less well in terms of positive prediction and specificity for ES of 0 or of 0/1 [possibly due to irreversibility of increased stool frequency in some patients because of irreversible structural damage], combining SFS with RBS offered the highest PPV, NPV, sensitivity and specificity when considering an ES of 0/1 and the highest PPV and specificity when considering an ES of 0. The importance of including endoscopic healing in definitions of remission in UC is reinforced by studies that have shown endoscopic healing could impact long-term outcomes for patients, such as relapse-free survival, the need for colectomy 20, 21 and future cancer risk. 22, 23 Both the FDA 3 and the EMA 4 accept an ES score of 1 within their criteria for clinical remission. Moreover, professional organizations such as the World Gastroenterology Organization 24 and the American College of Gastroenterology 25 do not provide explicit criteria for defining deep remission. The most recent definition is that issued by ECCO, which describes it as stool frequency ≤3 per day with no bleeding and no mucosal lesions at endoscopy. 5 Consequently, there is a lack of consensus about appropriate definitions of deep remission for use in the evaluation of new treatments for UC or for the evaluation of patients in routine clinical practice. CI, confidence interval; ITT, intention to treat; NPV, negative predictive value; PPV, positive predictive value; RBS, rectal bleeding score; SFS, stool frequency score; VDZ, vedolizumab.
a Includes all patients who responded to VDZ induction therapy at Week 6 and were subsequently randomized to placebo, VDZ Q4W or VDZ Q8W maintenance therapy.
The current analysis has addressed the issue of a lack of consensus on definitions of deep remission through evaluation of four definitions differing in the stringency of symptomatic and endoscopic criteria. A potential risk of using less stringent criteria to define deep remission is that patients who might benefit from further treatment optimization may be overlooked, with a subsequent negative impact on their long-term outcomes. Such patients may also experience persistent decrements to their health-related quality of life [HRQoL] .
A previous post hoc analysis of GEMINI 1 data highlighted that the achievement of clinical remission at Week 52 was associated with improved clinical and HRQoL outcomes. 26 The lack of standardization in defining deep remission further complicates the clinical evaluation of new treatments for UC, because it precludes comparison of deep remission rates across studies using different definitions. A patient defined as being in deep remission in one study may not have met the more stringent criteria applied in another study. In this way, the efficacy of some new treatments may be over-estimated in terms of their potential to optimize long-term outcomes for patients. In the GEMINI 1 study, patients administered vedolizumab Q4W showed a consistent trend of higher trough serum vedolizumab concentrations compared to patients administered vedolizumab Q8W. 27 The present analysis demonstrates a relationship between vedolizumab pharmacokinetics and deep remission, suggesting a trend towards higher rates of deep remission at Week 52 with higher trough serum steady-state concentrations. These observations support another recent evaluation of the relationship between vedolizumab trough concentrations and clinical outcomes utilizing data from the GEMINI 1 study, which found a relationship between higher vedolizumab trough serum concentrations and early [Week 6] clinical remission rates. 15 Interestingly, this latter analysis highlighted that patients who were anti-TNFα-naive were more likely to achieve clinical remission than patients who had failed previous anti-TNFα treatment. 15 An analysis of Week 6 deep remission rates by vedolizumab trough serum concentrations supports the previous evaluation of clinical remission rates, demonstrating a pattern of numerically higher deep remission rates at Week 6 for those achieving higher vedolizumab serum trough concentrations. The relatively low rates of deep remission at Week 6 across all four definitions evaluated in the current study suggest that deep remission may represent a more appropriate target for longer-term maintenance therapy than for acute, induction therapy.
Faecal calprotectin is a well-studied biomarker of intestinal inflammation in patients with inflammatory bowel disease. [28] [29] [30] In a recent study of 68 patients with UC, Patel et al. 31 showed that faecal calprotectin levels were significantly associated with disease extent based on the Montreal Classification, 32 Mayo score and Nancy score. 33 These authors also reported that faecal calprotectin levels of ≤60 µg/g predicted deep remission [defined by RBS = 0, SF ≤ 2 and endoscopic Mayo score = 0], with a sensitivity of 86% and a specificity of 87%. The results of the current analysis are consistent with these findings. We have shown that patients with UC who had faecal calprotectin levels ≤50 µg/g had significantly higher rates of deep remission at Week 52 than patients with faecal calprotectin levels >250 µg/g for all definitions of deep remission.
A further potential component of any definition of remission in UC is that of histological remission. 34 Preliminary evaluations suggest that histological remission may outperform endoscopic healing as a predictive marker for disease progression and response to therapy. 35, 36 This may be due to the identification of patients with residual microscopic inflammation who are at increased risk for symptomatic relapse than are those with normal histology. 37 Histological remission could represent a more stringent definition for remission in UC for the evaluation of new drug treatments. In this context, it will also be important to understand what differentiates patients who achieve deep remission with therapy from those who do not. Such understanding may inform treatment decisions and expectations, and aid in decisions to modify therapy in patients with persistent symptoms.
The post hoc nature of the analysis and the lack of histological data mandates further evaluation of the ability of vedolizumab to achieve deep and sustained remission in patients with UC. The current analysis is limited by the fact that it did not include an evaluation by prior anti-TNFα antagonist use, which is known to have an impact on other clinical outcomes. 38 The strengths of the current analysis lie in the comparison of a range of definitions of deep remission that varied in stringency of criteria, and the analysis of patients who were randomized and blinded to both induction and maintenance therapy regimen.
In conclusion, this post hoc analysis of data from the phase 3 GEMINI 1 trial conducted in patients with moderately to severely active UC has shown that treatment with vedolizumab was associated with significantly higher rates of deep remission than placebo at Week 52, regardless of dosing frequency or definition of deep remission. More than 40% of vedolizumab-treated patients vs up to 15.9% of those who received placebo achieved deep remission, measured by improvements in endoscopic healing and symptomatic patient-reported outcomes. 
